Chad Robins Sells 182,891 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CEO Chad Robins sold 182,891 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $15.99, for a total value of $2,924,427.09. Following the completion of the transaction, the chief executive officer owned 2,276,354 shares in the company, valued at $36,398,900.46. The trade was a 7.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Adaptive Biotechnologies Price Performance

Shares of Adaptive Biotechnologies stock opened at $16.44 on Thursday. Adaptive Biotechnologies Corporation has a 1 year low of $6.26 and a 1 year high of $20.76. The stock has a fifty day moving average price of $16.85 and a 200-day moving average price of $15.79. The firm has a market cap of $2.53 billion, a PE ratio of -41.10 and a beta of 2.19.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The firm had revenue of $71.68 million for the quarter, compared to analysts’ expectations of $59.38 million. During the same period in the previous year, the company earned ($0.23) earnings per share. The company’s quarterly revenue was up 51.0% on a year-over-year basis. As a group, equities analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

More Adaptive Biotechnologies News

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Company reported a quarterly earnings beat with strong revenue growth (revenue up ~51% YoY), which underpins the stock’s positive momentum. MarketBeat ADPT summary
• Positive Sentiment: Several sell-side firms raised price targets or reiterated Buy/Overweight ratings (Guggenheim, JPMorgan, Piper Sandler, Wall Street Zen), giving investors analyst support for higher valuations. Analyst coverage summary
• Neutral Sentiment: Reported short-interest entries show 0 shares (days-to-cover 0.0) — this appears to be a data error or non-material and shouldn’t be interpreted as meaningful short activity. (No actionable link.)
• Neutral Sentiment: Small institutional activity: several funds reported modest new or increased positions in the fourth quarter; institutional ownership remains high (~99%), so movements are incremental. MarketBeat ownership note
• Negative Sentiment: CEO Chad Robins executed multiple large sales in late Feb–early Mar (including 53,083 shares on Mar 3 and larger blocks on Mar 2 and Feb 27), reducing his stake materially; large insider sales can create short-term selling pressure or raise governance/insider-confidence questions. Chad Robins sale alert
• Negative Sentiment: Director/insider Harlan S. Robins also sold smaller blocks (10,000 and 14,233 shares on Mar 2–3), further increasing headline insider selling volume. Harlan S. Robins filings

Hedge Funds Weigh In On Adaptive Biotechnologies

A number of institutional investors and hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd purchased a new position in shares of Adaptive Biotechnologies in the fourth quarter worth approximately $28,000. Sound Income Strategies LLC bought a new position in shares of Adaptive Biotechnologies in the third quarter worth about $30,000. EverSource Wealth Advisors LLC grew its holdings in Adaptive Biotechnologies by 197.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after buying an additional 1,565 shares in the last quarter. Assetmark Inc. grew its stake in Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after acquiring an additional 2,708 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new position in shares of Adaptive Biotechnologies during the fourth quarter valued at about $51,000. 99.17% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on ADPT shares. Guggenheim boosted their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. BTIG Research lifted their price objective on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Piper Sandler set a $21.00 price objective on shares of Adaptive Biotechnologies in a research note on Friday, February 6th. Finally, Morgan Stanley started coverage on shares of Adaptive Biotechnologies in a research report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 target price for the company. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Adaptive Biotechnologies presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.25.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.